Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard Chemical & Pharmaceutical Co (TPE:1720) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Standard Chemical & Pharmaceutical Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$13,158 Mil.
Standard Chemical & Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,699 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard Chemical & Pharmaceutical Co EV-to-EBIT Related Terms
Standard Chemical & Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard Chemical & Pharmaceutical Co EV-to-EBIT Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Standard Chemical & Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard Chemical & Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Standard Chemical & Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Standard Chemical & Pharmaceutical Co's EV-to-EBIT falls into.
Standard Chemical & Pharmaceutical Co's current Enterprise Value is NT$12,874 Mil.
Standard Chemical & Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,699 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard Chemical & Pharmaceutical Co (TPE:1720) has a EV-to-EBIT of 7.58 as of Sep. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Standard Chemical & Pharmaceutical Co and its competitors. This is 20% below median its historical median of 9.53. Over the past decade, Standard Chemical & Pharmaceutical Co's EV-to-EBIT has ranged from 7.10 to 14.64. According to the industry distribution chart, Standard Chemical & Pharmaceutical Co ranks #138 out of 683 companies in the Drug Manufacturers industry, placing it in the top 20.2%.
Is Standard Chemical & Pharmaceutical Co's EV-to-EBIT too high?
Standard Chemical & Pharmaceutical Co's current EV-to-EBIT of 7.58 is 20% below median its 10-year median of 9.53. Over the past 10 years, this metric has ranged from a low of 7.10 to a high of 14.64. The Drug Manufacturers industry median EV-to-EBIT is 16.09. Standard Chemical & Pharmaceutical Co's value of 7.58 is 52.9% below this industry median. Based on the distribution chart, Standard Chemical & Pharmaceutical Co ranks #138 out of 683 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Standard Chemical & Pharmaceutical Co has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Standard Chemical & Pharmaceutical Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Standard Chemical & Pharmaceutical Co ranks #138 out of 683 companies for EV-to-EBIT. This places Standard Chemical & Pharmaceutical Co in the top 20% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 16.09. Standard Chemical & Pharmaceutical Co's value of 7.58 is 52.9% below this benchmark. Historically, Standard Chemical & Pharmaceutical Co's own EV-to-EBIT has ranged from 7.10 to 14.64 over the past decade. While the company's 10-year median is 9.53 vs. the industry median of 16.09, Standard Chemical & Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.09, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Standard Chemical & Pharmaceutical Co's current EV-to-EBIT of 7.58 is 52.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Standard Chemical & Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard Chemical & Pharmaceutical Co's current EV-to-EBIT is 7.58, which is 20% below median its own 10-year median of 9.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard Chemical & Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Standard Chemical & Pharmaceutical Co (TPE:1720) is currently considered Fairly Valued. The stock's GF Value™ is NT$58.98, compared to a current price of NT$56.10 — trading 4.9% below its estimated fair value. The current EV-to-EBIT is 7.58, which is 20% below median its 10-year median of 9.53 and 52.9% below the Drug Manufacturers industry median of 16.09. Standard Chemical & Pharmaceutical Co's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Standard Chemical & Pharmaceutical Co (TPE:1720), the current EV-to-EBIT is 7.58 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard Chemical & Pharmaceutical Co (TPE:1720) Overvalued in 2026?
Based on GuruFocus' analysis, Standard Chemical & Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$56.10 is trading 4.9% below its estimated GF Value™ of NT$58.98.
GuruFocus considers Standard Chemical & Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TPE:1720:
EV-to-EBIT: 7.58 (20% below median its 10-year median of 9.53)
GF Value™: NT$58.98 vs. price of NT$56.10 (4.9% below fair value)
Industry Position: 52.9% below the Drug Manufacturers median (#138 of 683)
No single metric tells the full story. See the TPE:1720 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard Chemical & Pharmaceutical Co Ltd is engaged in the manufacturing and sales of Chinese and western medicine, cosmetics, beverage, normal instruments and medical instruments. Its segments include Medicine, Dietary supplement and Ingredients. The majority of the revenue is derived from the Medicine segment. Geographically it operates in Taiwan, Japan and Others with Taiwan generating the maximum revenue.
96GF Score
Get the complete analysis for TPE:1720
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1720 has been successfully added to your 
